pp 1–1 | Cite as

Correction to: Benefit:Risk Profile of Budesonide in Obstructive Airways Disease

  • Donald P. TashkinEmail author
  • Brian Lipworth
  • Ralph Brattsand

1 Correction to: Drugs (2019) 79:1757–1775

Page 5, Fig. 2 Key milestones in the development of budesonide.

Box that currently reads ‘First approval of budesonide nebuliser solution for use in asthma 1992’

Should read:

‘First approval of budesonide nebuliser suspension for use in asthma 1992’

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of MedicineUniversity of California Los AngelesLos AngelesUSA
  2. 2.Scottish Centre for Respiratory Research, Division of Molecular and Clinical MedicineNinewells Hospital and Medical SchoolDundeeUK
  3. 3.Experimental PharmacologyBudera CompanyKristinehamnSweden

Personalised recommendations